Abstract
In the past, lower urinary tract symptoms (LUTS) in men over 40 years were always attributed to the enlarged prostate. The common term which was used in the medical world was benign prostatic hyperplasia (BPH), which is merely a histological diagnosis. Benign prostatic enlargement (BPE) means an enlarged prostate, with or without symptoms, whereas benign prostatic obstruction (BPO) is a urodynamic term which can only be diagnosed after pressure-flow studies and is defined by bladder outlet obstruction (BOO) due to BPE (Table 41.1). We know that other factors other than prostate enlargement contribute to LUTS, such as overactive bladder (OAB), detrusor underactivity, and nocturnal polyuria.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132(3):474–9.
Verhamme KM, Dieleman JP, Bleumink GS, van der Lei J, Sturkenboom MC, Artibani W, Begaud B, Berges R, Borkowski A, Chappel CR, Costello A, Dobronski P, Farmer RD, Jiménez Cruz F, Jonas U, MacRae K, Pientka L, Rutten FF, van Schayck CP, Speakman MJ, Sturkenboom MC, Tiellac P, Tubaro A, Vallencien G, Vela Navarrete R, Triumph Pan European Expert Panel. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care–the Triumph project. Eur Urol. 2002;42(4):323–8.
Roehrborn CG, Malice M, Cook TJ, Girman CJ. Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials. Urology. 2001;58(2):210–6.
Marberger MJ, Andersen JT, Nickel JC, Malice MP, Gabriel M, Pappas F, Meehan A, Stoner E, Waldstreicher J. Prostate volume and serum prostate-specific antigen as predictors of acute urinary retention. Combined experience from three large multinational placebo-controlled trials. Eur Urol. 2000;38(5):563–8.
Michel MC, Mehlburger L, Bressel HU, Goepel M. Comparison of tamsulosin efficacy in subgroups of patients with lower urinary tract symptoms. Prostate Cancer Prostatic Dis. 1998;1:332–5.
McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, Albertsen P, Roehrborn CG, Nickel JC, Wang DZ, Taylor AM, Waldstreicher J. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med. 1998;338(9):557–63.
Kaplan SA, Lee JY, Meehan AG, Kusek JW, MTOPS Research Group. Long-term treatment with finasteride improves clinical progression of benign prostatic hyperplasia in men with an enlarged versus a smaller prostate: data from the MTOPS trial. J Urol. 2011;185(4):1369–73. doi:10.1016/j.juro.2010.11.060. Epub 2011 Feb 22.
Roehrborn CG, Siami P, Barkin J, Damião R, Becher E, Miñana B, Mirone V, Castro R, Wilson T, Montorsi F, CombAT Study Group. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study. Eur Urol. 2009;55(2):461–71. doi:10.1016/j.eururo.2008.10.037. Epub 2008 Nov 6.
Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA. 2006;296(19):2319–28.
Oelke M, Giuliano F, Mirone V, et al. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol. 2012;61:917–25.
Van Kerrebroeck PE, Dmochowski R, FitzGerald MP, Hashim H, Norgaard JP, Robinson D, Weiss JP. Nocturia research: current status and future perspectives. Neurourol Urodyn. 2010;29(4):623–8.
Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, N’dow J, Nordling J, de la Rosette JJ. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2013;64(1):118–40.
Madersbacher S, Marberger M. Is transurethral resection of the prostate still justified? Br J Urol. 1999;83:227–37.
Mamoulakis C, Ubbink DT, de la Rosette JJ. Bipolar versus mono- polar transurethral resection of the prostate: a systematic review and meta-analysis of randomized controlled trials. Eur Urol. 2009;56:798–809.
Westenberg A, Gilling P, Kennett K, Frampton C, Fraundorfer M. Holmium laser resection of the prostate versus transurethral resection of the prostate: results of a randomized trial with 4-year minimum long-term followup. J Urol. 2004;172:616–9.
Rosario DJ, Phillips JT, Chapple CR. Durability and cost-effectiveness of transurethral needle ablation of the prostate as an alternative to transurethral resection of the prostate when alpha-adrenergic antagonist therapy fails. J Urol. 2007;177(3):1047–51.
Hoffman RM, Monga M, Elliott SP, et al. Microwave thermotherapy for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2012:9:CD004135.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Rom, M., Shariat, S. (2014). Non-neurogenic Male Lower Urinary Tract Symptoms (incl. Benign Prostatic Hyperplasia). In: Merseburger, A., Kuczyk, M., Moul, J. (eds) Urology at a Glance. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-54859-8_41
Download citation
DOI: https://doi.org/10.1007/978-3-642-54859-8_41
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-54858-1
Online ISBN: 978-3-642-54859-8
eBook Packages: MedicineMedicine (R0)